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Ethnopharmacological  relevance:  Traditional  Chinese  Medicine  (TCM),  including  Traditional  Chinese
Medicine  drugs  (TCM  drugs),  has been  playing  a  very  important  role  in  health  protection  and  disease
control  for  thousands  of  years  in China.  Relying  on  natural  products,  mainly  of herbal  origin,  used  either
as raw  materials  for  decoction,  as  prepared  herbal  medicines  or  as  formulated  traditional  medicines,
TCM  is  still  widely  accepted  by Chinese  people,  especially  for  chronic  diseases  treatment.  This  extensive
use warrants  safety  measures  and  so  TCM  drug  safety  monitoring  and  risk  management  are becoming
increasingly  important  tasks  for the Chinese  State  Food  and  Drug  Administration  (SFDA).
Methods:  The  Adverse  Drug  Reaction  (ADR)  monitoring  system  in  China  was  established  both  for  western
and  TCM  drugs  in 1989  as  a voluntary  reporting  system  with  a National  Center  collecting  and  compiling
reports.  Serious  or multi-case  reports  on individual  TCM  drug  or formulated  products  are  detailed  in
the Chinese  ADR  Information  Bulletin  to  inform  the  public  and  Drug  Administrative  authorities  for  risk
management.
Results:  About  10–15%  of  the ADR  reports  received  by the  National  Center  are  related  to  TCM  drugs
and  mainly  pertaining  to  the formulated  products.  In  certain  cases,  the  suspension  of  a particular  TCM
preparation  is decided  by  SFDA  China.
Conclusion:  The  model  of  safety  monitoring  and  risk  management  of  TCM  drugs  is  still under  exploration.
Indeed,  the characteristics  and  risk  factors  associated  with  these  drugs  require  both  proper  understanding
and  control  of  the  risk  by strengthening  standardization  of  clinical  applications,  basic  science  research,
quality  control  in manufacturing,  exploration  of the  actives  monitoring  methodology  and  enhancement
of  international  communication  and  cooperation.. IntroductionWith the increasing acceptance of Traditional Chinese Medicine
TCM), including Traditional Chinese Medicine drugs (TCM drugs),
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the role of TCM in global health care is being increasingly recog-
nized. In recent years, the drug safety monitoring organizations in
China have made great efforts in the assessment and monitoring
of Traditional Chinese Medicine drugs safety, implementing and
enforcing risk control measures to ensure safe drug use. The devel-
opment of the Adverse Drug Reaction (ADR) surveillance system
has led to an increase in safety alert reports on Traditional Chinese
Medicine preparations. The present paper presents a review on the
Open access under CC BY-NC-ND license.practice of drug safety surveillance in China and provides a perspec-
tive on the future developments of pharmacovigilance, taking into
account the special characteristics of Traditional Chinese Medicine
drugs.
5 opharmacology 140 (2012) 519– 525
2
2
e
c
h
M
i
a
1
o
m
a
S
2
M
l
o
f
m
s
m
a
c
a
i
P
t
t
w
i
a
A
i
f
2
i
h
r
i
m
A
o
a
G
s
w
T
2
r
2
1
8
r
a
c
r20 L. Zhang et al. / Journal of Ethn
. Overview of the pharmacovigilance system in China
.1. Regulation
Prior to 1989, the Chinese Ministry of Health (MOH) had already
stablished 10 Pilot Monitoring Units across the country; the data
ollection was mainly via literature survey, and case reports from
ospitals and patients. The ADR Monitoring Center of the Chinese
inistry of Health (MOH) was established in 1989 with responsibil-
ty for both types of drugs. In 1998, the Monitoring Center became
 member of the WHO  International drug monitoring program. In
999, the National ADR Monitoring Center improved regulation,
rganization and network infrastructure across China. The ADR
onitoring system plays an essential role in identifying, reporting
nd managing drug safety events.
A series of regulations between 1999 and 2011 by MOH  and
FDA have advanced the performance of the Centre. Especially in
011, a further revision of the “Adverse Drug Reaction Reporting and
onitoring Provision” (MOH  and SFDA, 2011) was issued. This pub-
ication clariﬁed the responsibilities of the ADR monitoring bodies
f the local and provincial level (municipal, provincial or county),
urther standardized the procedures of ADR reporting and manage-
ent, including the procedures for investigation and veriﬁcation on
erious ADR or mass ADR. It also strengthened the roles of phar-
aceutical manufacturers, raised the technical standard of ADR
ssessment to advocate ADR research and notably introduced con-
epts of focus monitoring and ADR information management. In
ddition, other regulations provide articles related to ADR mon-
toring. For example, in chapter 10 of the “Good Manufacturing
ractice For Drugs (2010 Revision)” (MOH  and SFDA, 2010), the sec-
ion “Complaints and adverse reaction reports” was  specially set up
o strengthen the responsibility of pharmaceutical manufacturers
ith requirements for a dedicated ADR monitoring team to collect,
nvestigate and manage ADR reports, take control of drug risk man-
gement and report ADRs to the Pharmaceutical Supervisory and
dministrative Department. The assessment procedures of safety
ssues has been improved through the promotion of ADR research,
ocused monitoring, and ADR information management.
.2. Organizations
In addition to the SFDA National Adverse Drug Reaction Mon-
toring Center afﬁliated to the Chinese Ministry of Health, China
as also established 34 provincial level monitoring branches. In
ecent years, the number of electronic submission users is steadily
ncreasing. In 2010, there were 40,826 registered users (the phar-
aceutical manufacturers and health care providers that can ﬁle
DR case reports via electronic submission system) on the network,
f which 21,785 (53.4%) are medical institutions, 15,919 (39.0%)
re enterprises, and 3122 (7.6%) are individuals and other users.
eneral public can also ﬁle case report(s) through phone calls, fac-
imiles to municipal, provincial monitoring center, a report form
ill be ﬁlled out by the staff in the monitoring center) (SFDA, 2011).
he current ﬂow-chart for reporting is presented in Fig. 1.
The number of ADR reports rapidly increased between 1999 and
007 but slowed after 2008. The National ADR Monitoring Center
eceived a total of over 3150,000 reports by the end of 2010. In
010 alone, 692,904 case reports were received of which nearly
10,000 were unexpected and serious ADRs. This is an increase of
.4% compared to 2009.
Traditional Chinese Medicine drugs represent 13.8% of total caseeports, involving more than 2400 products. Of these, the majority
re formulated products (99.7%) with less than 0.4% from Chinese
rude drugs. Unexpected and serious TCM drugs case reports rep-
esent 12.2% of total unexpected and serious reports (SFDA, 2010).Fig. 1. The current ﬂow-chart for ADR reporting in China.
2.3. Infrastructure
A nationwide computerized ADR surveillance information sys-
tem was established in 2003, rendering real-time online reporting
possible. Systems were developed including protocols for data
collection, case deﬁnitions, follow-up and assessment, diagnostic
criteria for adverse reactions and procedures for communication
with pharmaceutical manufacturers on safety issues and focused
surveillance of essential medicines. A powerful computational plat-
form supports the data storage and processing, identiﬁcation of risk
signals and overall evaluation. The measurements and decisions,
such as focus monitoring, prescription information revision, sus-
pension or withdrawal from market are made in accordance with
the evaluation results.
Through this network the National ADR Monitoring Center iden-
tiﬁed a series of drug safety problems, such as the Clindamycin
Phosphate Glucose Injection (Xinfu) event (Jing et al., 2007; Du
et al., 2008) or the Ciwujia Herbal Injectable event (Du et al., 2008;
Hu et al., 2010).
These drugs safety risks were efﬁciently controlled after timely
and appropriate assessment.
Although the ADR surveillance in China has grown rapidly and
made remarkable achievements, progress is still needed in areas of
post marketing research and regular re-evaluation of products.
3. Characteristics of Traditional Chinese Medicine drugs
and their risk factors
TCM drugs, like conventional drugs, can cause adverse reactions
which are an inherent property that accompanies the therapeu-
tic efﬁcacy of drugs. Besides the known potential ADR risk that
can arise when a drug is developed or used under the guidance
of TCM theory, there are numerous other risk factors affecting the
Traditional Chinese Medicine drugs safety which are due to the
characteristics of the drug per se or to its clinical usage.
3.1. Risk factors arising from the drug
The quality of the drug is one of the most important factors
affecting Traditional Chinese Medicine drugs safety. The safety fac-
tors related to drug quality include the following aspects.3.1.1. Raw herbals
3.1.1.1. Species and origin. The vast and diverse land area of China
nourishes a large reservoir of TCM drugs, notably of herbal origin.
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owever this diversity contributes to the complexity of the species
sed, their origins and names. Already the naming issues, including
he same name for different herbs, different names for the same
erb, similar name or abbreviation for totally different species, can
ead to considerable confusion.
.1.1.2. Place of origin and collection. TCM clinical practice consid-
rs the place of origin of the herbs as an important factor. Herbs
rom some designated areas are considered as Didao (place of
rigin) and thought to be of superior quality. Differences in the
rowing conditions and geographical origin may  indeed inﬂuence
he chemical proﬁles of the plants so that the same species from
ifferent locations can have different therapeutic efﬁcacy and tox-
city.
.1.1.3. Natural environment. Pollution of collecting sites may
mpact Traditional Chinese Medicine drugs safety due to contami-
ation with pesticides, heavy metals or radioactivity.
.1.1.4. Processing. Different methods of processing are used to
odify the properties of the medicinal herbs, presumably to reduce
oxicity and/or increase therapeutic activity. Precise and standard-
zed processing is required to reduce the potential toxicity of some
raditional medicines. For example, Cinnabaris (mercury(II) sulﬁde)
s insoluble and poorly absorbed from the gastrointestinal tract.
he traditional processing procedure by water grinding partially
emoves the hepatotoxic and nephrotoxic soluble mercury salt and
ree mercury. However, heat from inadequate processing with ball
rinding may  result in free mercury generation (Liu et al., 2008).
ncontrolled processing can also induce toxic components, with
he well-known example of smoking that may generate carcino-
enic polycyclic aromatics in treated material (Zhao et al., 2010).
.1.1.5. Storage. Ancient Traditional Chinese Medicine drugs mer-
hants used to take the storage and transportation very seriously
s these may  have great impact on the quality and efﬁcacy of
 medicine. For example inappropriate storage conditions can
hange the amygdalin content, affecting the therapeutic activity
f the Prunus armeniaca L. Var. ansu Maxim. seeds (Semen Arme-
iacae amarum, Ku Xing Ren). Standardized protocols are essential
o avoid deterioration, reduction in essential oils content, bacte-
ial, fungal or chemical contaminations. Bad practice resulted in
igh nicotine levels in Chinese dried mushrooms (Anastassiades
nd Fernandez-Alba, 2009) and bacterial contamination of Ciwujia
njection (Du et al., 2008; Hu et al., 2010).
.1.2. Inactive ingredients
Alcohol, oil, vinegar, honey are used in Traditional Chinese
edicine drugs as and sometimes also for their pharmaceutical
ctivity. Quality control of excipients used for processing herbs is
specially important as they may  introduce toxic contaminants, as
s the case when frying in peroxided oils. Ideally, only excipients of
harmaceutical quality should be used.
.1.3. Manufacturing
As stated in Section 3.1.1, good practice and standardized
anufacturing are crucial to the quality of Traditional Chinese
edicine drugs. Manufacturers should strictly follow the crite-
ia for the identiﬁcation of the medicinal herbs with stringent
uality control from the very beginning of the process, observing
ood practice standards, notably those foreseen in “Good Agricul-
ural Practice for Chinese Crude Drugs (Interim)” (SFDA, 2002), “Good
anufacturing Practice for Drugs (2010 Revision)” (MOH  and SFDA,
011), “WHO  guidelines on good agricultural and collection practices
GACP) for medicinal plants”  (WHO, 2003). Every procedure of theacology 140 (2012) 519– 525 521
manufacturing should be standardized to eliminate operational
error or management negligence.
3.1.4. Defects of the prescribing information/package leaﬂet
The prescribing information and package leaﬂet are an impor-
tant reference for clinician and patients, providing an important
guide for rational drug use and administration. The accuracy of
this information is crucial to the safe use of a medicine. Currently,
the prescribing information for some Traditional Chinese Medicine
drugs is not clear and details of indications, contraindications, spe-
cial warnings, special precautions for use and interactions may  be
overly simplistic and not reﬂect known risks. For example, the pre-
scribing information of Yimucao Injection from one manufacturer
only lists the indication as “Uterine contraction drug. Use to stop
bleeding and regulate menstruation”. This is inadequate for accu-
rate clinical use of the medicine, as it provides no information on
the TCM diagnosis and the symptom complex differentiation, not
reﬂecting the function of “mobilizing stagnated blood, dissipating
stasis, regulating menstrual period and stopping bleeding”.
3.1.5. Limitations of pre-marketing safety studies
It is largely recognized that pre-clinical tests and clinical tri-
als are not fully adequate assessments for drug safety due to the
limitations of animal models and small number of human subjects.
Pharmaceutical companies should be actively involved in post mar-
keting surveillance of drugs as this reﬂects large scale use of a drug
in patients with concomitant diseases and treatments and varied
compliance. This is important in early identiﬁcation of new adverse
reactions, herb/drug interactions and for better risk control.
3.1.6. Adulterated and counterfeit drugs
Except for SFDA-approved Chinese and Western compound
products, the addition of Western drugs into a Traditional Chinese
Medicine drug formula is illegal. SFDA has established examina-
tion methods and shelf sampling inspection of products in order to
protect the safety of the patients.
3.2. Factors in clinical use
3.2.1. Lack of TCM theoretical guidance
The use of a TCM drug without an appropriate diagnosis of
the patient’s TCM complex of symptoms is another important
risk factor. The TCM diagnosis should differentiate the correct
symptom-complex of the patient before prescribing a Chinese
medicinal herbal formulation or a TCM proprietary product to a
patient (Jiang et al., 2012). The practitioner should have a solid
knowledge of TCM theory, and carefully read and fully understand
the prescribing information. For example Shuanghuanglian Prepa-
rations are “cold in their herbal nature”, and should only be used to
“clear feverish toxicity and disperse wind-heat, such as fever, cough,
sore throat caused by the contagion of external wind-heat”.  While the
use of Shuanghuanglian Preparations for “cough caused by wind-
cold invasion” would be inappropriate.
Such symptom-complex differentiations are essential to TCM
practice and the failure to correctly discern the use of drugs poses
serious ADR risks. Therefore, TCM drugs should only be used under
the TCM theory guidance. The practice to modify the CMM  prescrip-
tion according to the patients’ response also minimizes unwanted
effects and improves efﬁcacy; such monitoring, if undertaken by a
trained practitioner, can reduce the severity of adverse effects.
In order to improve the current reporting system, the reporter
should, in the ADR surveillance reporting form, under the item of
“Patient’s General Information”, ﬁll out the patient’s diagnoses in
both “Western Medicine” and TCM terms, including the symptom-
complex differentiation. At present, for the coding of medical
conditions in the reports (diagnosis as well as adverse events) a
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urely Western terminology (WHOART) is used. Obviously this may
ave consequences for signal detection and the interpretation of
he data; sometimes artifactual distortions might occur.
.2.2. Failure to adhere to the prescribing information
As for any drug, the dosage and duration of use are important.
ut, although some of the TCM drugs have been well investigated
or pharmacological, pharmacokinetics and toxicological proper-
ies, there are insufﬁcient data for a large portion of individual
ateria medica and historically formulated medicines; therefore,
he dosing and timing of many TCM drugs is still largely based on
 long history of empirical practices. The administration of Tra-
itional Chinese Medicine drugs should be stopped as soon as
adequate effects have been achieved”, especially for the Traditional
hinese Medicine drugs that are toxic or contain toxic ingredients.
or example, Niuhuang Jiedu Tablets1 are for sore throat, swollen
ums, mouth sores and red painful eyes; while prolonged uses
r overdose can lead to arsenic poisoning (Guo and Pan, 2003).
he roots of Ligusticum chuanxiong Hort. (Rhizoma Chuanxiong,
huanxiong) can smoothen Qi and Blood circulation; however
verdose or chronic use of high doses can cause headache, nau-
ea and vomiting and dysuria. Ginkgo biloba L. seed can be used
s astringent in pulmonary disorders and for soothing coughing;
verdose causes irritability, seizure, and breathing difﬁculty, nau-
ea and vomiting, abdominal pain and in some cases death may
nsue.
Such endpoints are however highly subjective as they largely
epend either on the patient himself deciding “effects have been
chieved” or on a regular follow-up by hopefully experienced
ractitioners. As both scientiﬁc data and empirical historical docu-
entation are used to establish drugs at risk for ADR alert, there is
till some extent of subjectivity that needs to be improved.
.2.3. Inappropriate combination with Western medicines
It has become common practice that Traditional Chinese
edicine drugs are prescribed in combination with Western
edicines. Inappropriate combinations may  however be another
ommon cause of adverse reactions. For example, Anshen Buxin
apsules/pills contain Decoctum Tranquilizici Concentratum and
hould not be used with chemical drugs that contain bromide
nd/or iodide, as the combination can produce toxic mercury
romide or mercury iodide. Xiaoke Pill, a Chinese and Western com-
ound preparation containing glibenclamide, approved by SFDA,
hould not be used together with sulfonylurea anti-diabetics, as
he combination can cause hypoglycemia.
.2.4. Inappropriate route and dosing and timing
The preferred methods of use of TCM drugs in terms of safety
re oral, intramuscular and then intravenous administration. As
iscussed in Section 3.2.2, the dosing and timing of Traditional
hinese Medicine drugs administration are still largely inherited
rom historical practice; except for some of the established for-
ulated drugs, most of the decoctions are usually prescribed at
 regimen of 2–3 times per day for oral use, depending on the
erbs and combinations used. Drugs for “toniﬁcation and replenish-
ent”, “spleen strengthening”  or anti-diarrhoeals should be given
efore meals. Vermifuges should be taken early in the morning
efore breakfast or in the evening before sleep. Sedatives should be
aken 1–2 h before sleep. Drugs to “defend from external invasion”
hould be given promptly with onset of the superﬁcial symptoms to
1 Formulation may  include: Bovis Calculus Artiactus, Realgar, Gypsum Fibrosum,
hei Radix et Rhizoma, Scutellariae Radix, Platycodi Radix, Borneolum Syntheticum
nd Glycyrrhizae Radix et Rhizoma (CP 2010).acology 140 (2012) 519– 525
prevent further development. Failure to follow such rules will affect
the efﬁcacy and the safety of the TCM drugs.
3.2.5. Incorrect preparation
The preparation of the TCM decoctions mainly relies on “rules of
thumb” as advised by the prescriber; for instance, the choice of con-
tainer and vessel, cooking-time, volume of water added, the order
of adding decoction pieces after boiling, the heat-intensity of cook-
ing, etc. should be followed. Incorrect or inappropriate preparation
method will both affect the therapeutic actions of the drug and
may  result in inadequate detoxiﬁcation. For example, the roots of
Aconitum carmichaeli Debx. (Radix Aconiti, Chuanwu) or the roots
of Aconitum kusnezofﬁi Reichb. (Radix Aconiti kusnezofﬁi, Caowu)
should be decocted separately to detoxify the alkaloids according
to a speciﬁed period or guided by the pharmacopoeia, whereas
the herb of Mentha haplocalyx Briq. (Herba Menthae haplocalycis,
Bohe) or Schizonepeta tenuifolia Briq. herb (Herba Schizonepetae
tenuifoliae, Jingjie) should be added at the end of decoction period;
otherwise the volatile active ingredients (essential or volatile oils)
will evaporate due to prolonged heating.
3.2.6. Individual factors
The patient’s disease, age, gender, diet and habits can all be
important factors that affect the efﬁcacy and the safety of a drug.
As a rule children and elderly patients usually have decreased
clearance of and tolerance to the medication and are thus more
susceptible to drug accumulation and intoxication. The general
health status, nutrition, pregnancy, allergy are also important fac-
tors affecting the metabolism or tolerance of a drug or severity of
adverse reactions. As there are often no scientiﬁc or validated clin-
ical data for “evidence-based use”, it is important to promote the
concept of “rational use of TCM drugs” to emphasize the patient
compliance to avoid unintentional overtreatment.
4. The practice of Traditional Chinese Medicine drugs risk
management in China
The present section will survey the general picture of drugs
(chemical and TCMs) risk management procedures, presenting
some representative cases in the ﬁeld of TCM drugs. Regarding tech-
nical aspects, the provisions for chemical drugs and TCM drugs are
quite similar. Indeed, given that the Chinese health system tends to
integrate Western and Chinese medicines with hospitals/doctors
providing both systems, the drug safety monitoring is quite sim-
ilar for the 2 systems. Particular aspects related to TCMs should
however be considered, as discussed in Section 5.2.
Signal identiﬁcation, risk assessment, communication and con-
trol are major components of pharmacovigilance; “repetitive
reevaluation and progressive improvement” is the core of the risk
management of a drug. Besides the technical aspect of risk assess-
ment, information and communication are important avenues to
drug (chemical and TCMs) use safety by enhancing the trans-
parency of decision making and by timely notifying patients and
clinicians of known risks. Currently, arrangements have been estab-
lished for drug safety in China, based on risk management and
decision making; Post-marketing risk management is still in an
early stage in China, but already now all drugs on the mar-
ket are being screened for ADR signals, risk evaluation and if
needed regulatory measures are taken. The further development
and improvement of pharmacovigilance of TCM drugs is a chal-
lenge for the future to integrate the number of ADR  reports with
the TCM quality aspects.
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species that contain aristolochic acids, including Guang Fangji (Aris-
tolochia fangchi Y. C. Wu ex L. D. Chow & S. M.  Hwang), Qing MuxiangL. Zhang et al. / Journal of Ethn
.1. Manufacturer communication meeting
In contrast with Europe and North America, 90% of ADR cases are
eported directly from hospitals or other medical service providers
n China. Drug manufacturers therefore need to recognize the
eﬁciencies of their own pharmacovigilance systems to be more
ctively involved in ADR monitoring. The administration strives
o provide a platform to bridge the manufacturers and hospi-
als, the “manufacturer communication meeting”. This platform aims
o feedback ADR reports to the manufacturer in an efﬁcient and
imely manner for efﬁcient drug risk control, to inform them about
ost-marketing drug safety issues and to discuss the strategies
nd methods for drug risk control. The latest regulation that was
ssued in 2011 enforced the manufacturers’ obligation in the report-
ng, follow-up, investigation and Periodical Safety Update Report
PSUR). For the drugs listed for focus monitoring, the new regula-
ion requires both voluntary reporting and active surveillance.
For example the manufacturers of a number of preparations
uch as Keyin Pill,2 Baishi Pill, Zhixue Pill, Lianbizhi injection have
ow strengthened their vigilance of drug risks and are aware of the
ecessities of voluntary risk control measures.
.2. Bulletin Press release
In November 2001 the SFDA launched the ADR information Bul-
etin release to openly, timely and efﬁciently inform the patients,
anufacturers and general public of ADRs and drug safety issues.
y November of 2011, 42 issues of ADR information Bulletin had
een published, listing 81 ADR Alerts (SFDA, 2011). Nine of these
11%) are “second” alerts as a result of newly identiﬁed ADRs;
hese included Puerarin Injection, Qingkailing/Shuanghuanglian
njection, Zhuanggu Guanjie Pill and Potassium Dehydroandro-
rapholide Succinate Injection. Of the 72 “ﬁrst” alerts, 12 concerned
CMs (5 injections and 7 oral preparations); an alert was  also issued
n aristolochic acid containing drugs.
.3. Revision of the prescribing information/package leaﬂet
Due to limitations of pre-marketing research, the information on
dverse reactions in the summary of product characteristics (SPC)
ay be incomplete or inaccurate. Therefore the SPCs need regular
evision to update the information adverse reactions, drug-drug
r drug-food interactions, warnings and contra indications and to
mit inaccurate information. The prescribing information should
e reworded to highlight the warnings of major potential ADRs
nd to provide information on the early diagnosis and treatment
f ADRs. The prescribing information of a series of Traditional Chi-
ese Medicine drugs has been revised accordingly to ensure safe
nd rational use; these include Baishi Pill, Keyin Pill, Qingkailing
njection, Shuanghuanglian Injection, Lianbizhi Injection, Yuxing-
ao Injection, Shenmai Injection, Biyanning Injection etc.
.4. Restriction on marketing and use
The marketing and clinical use of drugs that can potentially
ause adverse effects, but nevertheless have an acceptable bene-
t/risk ratio, for example because there is no better alternative;
n such cases restrictions as regards the use of the drug may  be
eeded. This may  include a change in status, restrictions of its use
2 Although SFDA certiﬁed and approved Chinese Traditional Patent Medicines
ave ﬁxed formulae, the exact composition that led to ADRs is not always known
ith certitude. To avoid misleading information, formulae have then not been
etailed.acology 140 (2012) 519– 525 523
to selected specialties and/or specialists or with a requirement of
informed consent from the patient.
4.5. Suspension
When the uncertainty regarding the safety of a drug has become
unacceptably high, the marketing authorization can be temporarily
suspended. Depending on further data, the suspension can either be
lifted or the drug can be permanently withdrawn from the market.
For example, on June 1, 2006, the National ADR Center
suspended all the manufacturing approval and clinical use of
Yuxingcao3 injection and 7 other related injections due to severe
ADRs, including deaths (SFDA, 2004). Inconsistency of the quality
of Traditional Chinese Medicine drugs, inappropriate processing,
such as the use of dried and not fresh Houttuynia cordata Thunb.
(Herba Houttyniae cordatae, Yu Xing Cao) and high Tween 80 con-
centration were deemed possibly the major causes of the ADR.
Following the suspension, the prescribing information was revised
after a scientiﬁc and clinical study review. The conditional lifting of
the suspension was granted 3 months later with measures taken to
enforce the surveillance and follow-up by the National ADR Center,
jointly with the manufacturers and the Provincial ADR Surveillance
Centers.
4.6. Withdrawal from the market of toxic TCM drugs and related
products
Withdrawal of a product from the market (termination of
marketing authorization) may  be voluntarily decided by the man-
ufacturer or mandatorily ordered by the administration whenever
a beneﬁt/risk assessment is not acceptable, when there is insufﬁ-
cient drug safety information or if measures to reduce the risk are
not available.
Of the 72 drugs listed in the published “ADR Information Bul-
letin” 2 drugs have been permanently withdrawn (including 1 TCM
drug) after careful study and evaluation. For example, after the “ADR
Information Bulletin” release concerning the adverse reactions to
LongdanXiegan Pill,4 the origin and history of the ingredient “Guan
Mutong” was  thoroughly reviewed. This clariﬁed a historical con-
fusion of species misuse. It was  found that, from the time of Ming
dynasty, when Li Dongyuan created the LongdanXiegan Decoction,
all the “Mutong” used in history was  either Akebia quinata Decne.,
Clematis armandii Franch. or Clematis Montana Buch.-Ham. ex DC.
The “Guan Mutong”, Caulis Aristolochiae manshuriensis, however
ﬁrst appeared in “The Annals of Jilin”, compiled during the years
of Kangxi Emperor of Qing dynasty and was used in the inland
China until 1930s. The faster growing herb with higher yield and
lower cost, Aristolochia manshuriensis Kom., gradually replaced the
Clematis throughout China; however, this CMM  (like all Aristolochia
species) contains aristolochic acids which cause nephrotoxicity
(“aristolochic acid nephropathy” or AAN). SFDA issued the “Notice
on Termination of the Medicinal Use of Guan Mutong” (SFDA, 2003)
and restored the Clematis armandii species in all preparations that
contain “Mutong”. This also terminated the medicinal uses of other(Aristolochia contorta Bunge).
3 Sterilized aqueous solution of fresh Houttuynia cordata Thunb.
4 Gentianae scabrae Radix, Bupleuri chinensis Radix, Alismatis orientalis Rhizoma,
Rehmanniae glutinosae Radix, Scutellariae baicalensis Radix, Gardeniae jasminoidis
Fructus, Tetrapanacis papyriferi Medulla, Plantaginis Semen (Plantagoasiatica),
Angelicae sinensis Radix, Glycyrrhizae uralensis Radix, Aristolochiae manshuriensis
Caulis.
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. The future of Traditional Chinese Medicine drugs
harmacovigilance in China
.1. Strengthen education, training and publicity
It is essential to improve the information communication on
raditional Chinese Medicine drugs to promote an objective view
f both their therapeutic beneﬁts and safety concerns among the
ublic and health professions. There is a need to correct the com-
only accepted concept that “Traditional Chinese Medicine drugs
re non-toxic”, but also to prevent the uneducated exaggeration of
afety issues.
The National ADR Monitoring Center has launched a nation-
ide training program targeting the staff of the Provincial and
unicipal Monitoring Centers. Currently, only some clinicians have
een systemically trained for TCM drugs ADR reporting; clearly fur-
her training of clinicians, physicians and pharmacists are needed
o enhance awareness, voluntary involvement and capabilities for
DRs identiﬁcation and assessment. This training should aim for
he early identiﬁcation, early intervention and early reporting of
CM drugs ADRs. This will improve the quality of reports and con-
ribute to enrich the database with relevant suspected cases.
Patients and general public should be alerted to the potentials
or adverse effects and encouraged to inform health professionals as
ell; indeed the TCM ADRs are directly or indirectly related to every
ingle people in the society. Awareness of TCM drugs ADR can be
nhanced by communication; one avenue is through the clinicians
nd pharmacists, another avenue is through events organized by
ifferent levels of Monitoring Centers; for example a booklet has
een published for general public education.
After a decade of efforts, the number of case reports has consid-
rably increased and has become stable in recent years. The quality
f reports has also been improved, with the ratio of severe cases
eports increased. The evaluation reports built by different levels
f agencies have become more consistent and reproducible. Pre-
iminary data show that, together with the public education, the
rrational use of TCM drugs is decreasing.
.2. Establish an effective pharmacovigilance system speciﬁc to
raditional Chinese Medicine drugs
The special characteristics of Traditional Chinese Medicine
rugs and their medicinal uses make post marketing safety mon-
toring an important component of drug safety evaluation. The
afety monitoring system of TCM drugs should not limited to ADRs
ut also cover the whole life cycle of a drug, from cultivation, col-
ection, processing, research and development to manufacturing
nd marketing. Indeed good manufacturing practice for production
equires implementing the full range of good practices, including
AP, GCP etc. and all their procedures, in each of these steps.
As discussed in Section 4, Traditional Chinese Medicine drugs
nd chemical medicines currently share the same voluntary report
ystem in China. This system however cannot cover all factors
hat affect TCM drugs safety. To improve the current monitor-
ng system, further pharmacovigilance procedures dedicated to
CMs should be established, in accordance with all their partic-
larities. This requires devising speciﬁc guidelines to: (i) build
edicated TCM drugs ADR reporting protocols taking into account
ll TCM characteristics; (ii) establish a focus monitoring machinery
ith the assistance from epidemiologists to compensate defects of
he voluntary monitoring report system; (iii) establish large clin-
cal medication databases to archive the details of clinical usage
f CMMs  and TCM products; (iv) draft safety monitoring proce-
ures for Traditional Chinese Medicine drugs; and (v) establish and
nhance clinical research and post-marketing risk management.acology 140 (2012) 519– 525
5.3. Prioritize the focus of Traditional Chinese Medicine drugs
safety surveillance
Traditional Chinese Medicine drugs mainly come from natural
sources and include a variety of presentations such as decoction
pieces, extracts/granules of the decoction pieces (known as Keli)
for TCM prescribing uses, proprietary Chinese medicines (PCM,
known as Zhong Cheng Yao or Fufang), and single ingredient herbal
products (not prepared according to TCM practice). Such a diver-
sity means that safety priorities have to be determined in order to
develop effective surveillance of TCM drugs.
Currently, the main monitoring targets are TCM drugs injections,
Chinese and Western compounds mixed preparations, formulae
containing known toxic materia medica and newly formulated TCM
drugs.
5.4. Strengthen the roles of pharmaceutical manufacturers as the
main body of Traditional Chinese Medicine drugs post-marketing
risk management
Pharmaceutical manufacturers should actively strengthen their
post-marketing safety surveillance as well as the clinical and basic
research of TCM drug products. Currently, most TCMs manufac-
turing companies in China lack, to a certain extent, the awareness
of risk management. Some manufacturers do not pay adequate
attention to safety surveillance and are not willing to report ADR
information because of a concern for negative impact on the mar-
ket. Their capability of drug risk identiﬁcation and management
is also insufﬁcient. Packaging and leaﬂets of some formulated
TCM products need to be thoroughly revised to provide adequate
instructions for safe clinical use.
So far, the majority of the ADR reports come from the health care
providers. From the data of 2010, only less than 13% of the reports
came from the manufacturers. Therefore, the voluntary monitoring
by the manufacturers needs to be further strengthened. As men-
tioned above in Sections 2.1 and 4.1,  a series of regulations are being
issued to further enforce the operation.
5.5. Promote the appropriate use of Traditional Chinese Medicine
drugs
Clinicians and pharmacists who  are dealing with the use
of TCM products should pay attention to the TCM syndrome-
complex differentiation and be aware of and monitor any
possible drug interactions (including TCM drugs–TCM drugs, TCM
drugs–pharmaceutical drugs and TCM drugs–food). In order to
ensure safe use of Traditional Chinese Medicine drugs injections,
the Ministry of Health, SFDA and State Administration of TCM of
the People’s Republic of China (SATCM) jointly issued “The Notice
on further strengthening the production, management and rational use
of Traditional Chinese Medicine drug injections” on 24th December
2008 (MOH, SFDA, SATCM 2008); this document formulates 7 basic
principles for the clinical use of TCM drug injections. In order to
standardize clinical use of TCM drugs, SATCM issued on 11th June,
2010 the “Guidelines on the Clinical Application of Traditional Chinese
Medicine drugs” (SATCM, 2010).
5.6. Communicate safety information to the relevant agencies for
cooperation to identify the nature of the ADRs
In order to ensure that regulatory decisions are taken on the
basic of solid scientiﬁc conclusions and to identify the real risk fac-
tors from the drug R&D, production or circulation, there is a need
to strengthen cooperation and Traditional Chinese Medicine drugs
safety information sharing among related drug regulatory agencies,
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o improve TCMs pharmaceutical standards and to combine drug
ampling examinations with pharmacovigilance signals.
.7. Establish an international coordinating database for adverse
eactions reporting and promote signal detection
The global interest in complementary and alternative medicine
as attracted much attention worldwide. Recently the awareness
f the need for surveillance of adverse reactions to natural health
roducts has stimulated the implementation of reporting systems
or suspected adverse reaction in many countries. A recent review
y Chan et al. (2011) critically assessed pharmacovigilance reports
n natural health products and other complementary treatments
ssued by the regulatory authorities in Australia, Canada, China, UK,
U and academic institutes in France, Germany, Greece, Italy, India
nd Korea. The experience from these different countries should be
tilized to reﬁne globalized herbal pharmacovigilance, epidemio-
ogical research and reporting machinery. So far, Europe and the
S have little access to in-depth data on the safety or toxicity of
CM drugs, as most reports remain in the Chinese language. A
lose collaboration with institutes in China facilitating access to
his information can be of great value in pharmacovigilance and an
nternational cooperation platform with standardized nomencla-
ure system for TCM drugs and standardized ADRs database is the
est option.
China is a member of the WHO  Programme for International
rug Monitoring. The Uppsala Monitoring Centre is the collaborat-
ng center that brings together these ADR reports from over 100
ountries around the world. In December 2010 of approximately 6
illion reports in the database, there were 12,679 herbal reports
UMC, 2012). The database will include TCM drugs adverse reac-
ion reports from around the world. This increased reporting facility
ringing together data from many countries may  help to identify
afety signals that would not be found from reports in a single
ountry.
. Conclusion
The safety of Traditional Chinese Medicine drugs is a concern
hroughout the whole life period of the drug. Although pharma-
ovigilance is an absolute requirement to ensure public safety
nd to promote the healthy development of TCM industry, other
easures should also been encouraged and implemented. Qual-
ty control remains one of the main issues in TCM drugs safety
oncerns. Standardization and enforcement of GMP  and manufac-
uring guidelines will support any safety initiative. These include:
i) strengthening TCM pharmaceutical manufacturers’ responsibil-
ty and awareness of drug quality and of the value of basic research
ork on their drug products; (ii) regulating clinical use; (iii) pro-
oting the cooperation and information sharing among the related
rug regulating agencies; and (iv) further enhancing international
xchanges.
Furthermore, active pharmacovigilance should be introduced
nto the monitoring and evaluation system of drugs on the marketacology 140 (2012) 519– 525 525
to gradually establish focused monitoring and risk-beneﬁt man-
agement system for post-marketing Traditional Chinese Medicine
drugs (Zhang and Yang, 2009). It is important that China eventu-
ally establishes a risk management model adapted to Traditional
Chinese Medicine practice characteristics.
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